Neurocrine Biosciences (NBIX) Capital Expenditures Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.12% |
| Dec 31, 2025 | 54.06% |
| Sep 30, 2025 | -43.61% |
| Jun 30, 2025 | 101.54% |
| Mar 31, 2025 | 52.44% |
| Dec 31, 2024 | 21.12% |
| Sep 30, 2024 | 18.27% |
| Jun 30, 2024 | 22.71% |
| Mar 31, 2024 | 12.89% |
| Dec 31, 2023 | 35.50% |
| Sep 30, 2023 | -25.92% |
| Jun 30, 2023 | 25.92% |
| Mar 31, 2023 | -19.73% |
| Jun 30, 2022 | 53.28% |
| Mar 31, 2022 | 41.04% |
| Dec 31, 2021 | -27.35% |
| Sep 30, 2021 | 73.74% |
| Jun 30, 2021 | -24.78% |
| Mar 31, 2021 | 43.44% |
| Dec 31, 2020 | -51.72% |